The Birmingham vasculitis activity score as a measure of disease activity in patients with giant cell arteritis

Tanaz A. Kermani, David Cuthbertson, Simon Carette, Gary S. Hoffman, Nader A. Khalidi, Curry L. Koening, Carol A. Langford, Kathleen McKinnon-Maksimowicz, Carol A. McAlear, Paul A. Monach, Philip Seo, Kenneth J Warrington, Steven R Ytterberg, Peter A. Merkel, Eric Lawrence Matteson

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective. To evaluate the performance of the Birmingham Vasculitis Activity Score (BVAS) in the assessment of disease activity in giant cell arteritis (GCA). Methods. Patients with GCA enrolled in a prospective, multicenter, longitudinal study with symptoms of active vasculitis during any visit were included. Spearman's rank correlation was used to explore the association of the BVAS with other measures of disease activity. Results. During a mean (SD) followup of 2.3 (1.6) years, symptoms of active GCA were present in 236 visits in 136 subjects (100 female, 74%). Median (range) BVAS1 (new/worse symptoms) was 1 (0-10) and median (range) BVAS2 (persistent symptoms) was 0 (0-5). Median (range) physician's global assessment (PGA) was 4 (0-9) for disease activity in the past 28 days and 2 (0-9) for activity on the day of the visit. Important ischemic manifestations of active vasculitis not recorded by the BVAS included tongue/jaw claudication (27%), upper extremity claudication (15%), lower extremity claudication (5%), carotidynia (7%), and ischemic retinopathy (5%). During 25 visits (11%) with active disease, all symptoms of active vasculitis were placed in the "Other" category yet still resulted in a BVAS1 and BVAS2 of 0. BVAS1 moderately correlated with PGA for the past 28 days (Spearman's correlation 0.50) and physician-rated disease activity for the past 28 days (Spearman's correlation 0.46). Conclusion. The BVAS has limited utility in GCA. Patients with active GCA can have a BVAS of 0. Many important ischemic symptoms attributable to active vasculitis are not included in the composite score.

Original languageEnglish (US)
Pages (from-to)1078-1084
Number of pages7
JournalJournal of Rheumatology
Volume43
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Giant Cell Arteritis
Vasculitis
Physicians
Jaw
Tongue
Upper Extremity
Multicenter Studies
Longitudinal Studies
Lower Extremity

Keywords

  • Birmingham Vasculitis Activity Score
  • Cohort Study
  • Disease Activity
  • Giant Cell Arteritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

The Birmingham vasculitis activity score as a measure of disease activity in patients with giant cell arteritis. / Kermani, Tanaz A.; Cuthbertson, David; Carette, Simon; Hoffman, Gary S.; Khalidi, Nader A.; Koening, Curry L.; Langford, Carol A.; McKinnon-Maksimowicz, Kathleen; McAlear, Carol A.; Monach, Paul A.; Seo, Philip; Warrington, Kenneth J; Ytterberg, Steven R; Merkel, Peter A.; Matteson, Eric Lawrence.

In: Journal of Rheumatology, Vol. 43, No. 6, 01.06.2016, p. 1078-1084.

Research output: Contribution to journalArticle

Kermani, TA, Cuthbertson, D, Carette, S, Hoffman, GS, Khalidi, NA, Koening, CL, Langford, CA, McKinnon-Maksimowicz, K, McAlear, CA, Monach, PA, Seo, P, Warrington, KJ, Ytterberg, SR, Merkel, PA & Matteson, EL 2016, 'The Birmingham vasculitis activity score as a measure of disease activity in patients with giant cell arteritis', Journal of Rheumatology, vol. 43, no. 6, pp. 1078-1084. https://doi.org/10.3899/jrheum.151063
Kermani, Tanaz A. ; Cuthbertson, David ; Carette, Simon ; Hoffman, Gary S. ; Khalidi, Nader A. ; Koening, Curry L. ; Langford, Carol A. ; McKinnon-Maksimowicz, Kathleen ; McAlear, Carol A. ; Monach, Paul A. ; Seo, Philip ; Warrington, Kenneth J ; Ytterberg, Steven R ; Merkel, Peter A. ; Matteson, Eric Lawrence. / The Birmingham vasculitis activity score as a measure of disease activity in patients with giant cell arteritis. In: Journal of Rheumatology. 2016 ; Vol. 43, No. 6. pp. 1078-1084.
@article{4d24e15b790645149847082cabc2c1c0,
title = "The Birmingham vasculitis activity score as a measure of disease activity in patients with giant cell arteritis",
abstract = "Objective. To evaluate the performance of the Birmingham Vasculitis Activity Score (BVAS) in the assessment of disease activity in giant cell arteritis (GCA). Methods. Patients with GCA enrolled in a prospective, multicenter, longitudinal study with symptoms of active vasculitis during any visit were included. Spearman's rank correlation was used to explore the association of the BVAS with other measures of disease activity. Results. During a mean (SD) followup of 2.3 (1.6) years, symptoms of active GCA were present in 236 visits in 136 subjects (100 female, 74{\%}). Median (range) BVAS1 (new/worse symptoms) was 1 (0-10) and median (range) BVAS2 (persistent symptoms) was 0 (0-5). Median (range) physician's global assessment (PGA) was 4 (0-9) for disease activity in the past 28 days and 2 (0-9) for activity on the day of the visit. Important ischemic manifestations of active vasculitis not recorded by the BVAS included tongue/jaw claudication (27{\%}), upper extremity claudication (15{\%}), lower extremity claudication (5{\%}), carotidynia (7{\%}), and ischemic retinopathy (5{\%}). During 25 visits (11{\%}) with active disease, all symptoms of active vasculitis were placed in the {"}Other{"} category yet still resulted in a BVAS1 and BVAS2 of 0. BVAS1 moderately correlated with PGA for the past 28 days (Spearman's correlation 0.50) and physician-rated disease activity for the past 28 days (Spearman's correlation 0.46). Conclusion. The BVAS has limited utility in GCA. Patients with active GCA can have a BVAS of 0. Many important ischemic symptoms attributable to active vasculitis are not included in the composite score.",
keywords = "Birmingham Vasculitis Activity Score, Cohort Study, Disease Activity, Giant Cell Arteritis",
author = "Kermani, {Tanaz A.} and David Cuthbertson and Simon Carette and Hoffman, {Gary S.} and Khalidi, {Nader A.} and Koening, {Curry L.} and Langford, {Carol A.} and Kathleen McKinnon-Maksimowicz and McAlear, {Carol A.} and Monach, {Paul A.} and Philip Seo and Warrington, {Kenneth J} and Ytterberg, {Steven R} and Merkel, {Peter A.} and Matteson, {Eric Lawrence}",
year = "2016",
month = "6",
day = "1",
doi = "10.3899/jrheum.151063",
language = "English (US)",
volume = "43",
pages = "1078--1084",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "6",

}

TY - JOUR

T1 - The Birmingham vasculitis activity score as a measure of disease activity in patients with giant cell arteritis

AU - Kermani, Tanaz A.

AU - Cuthbertson, David

AU - Carette, Simon

AU - Hoffman, Gary S.

AU - Khalidi, Nader A.

AU - Koening, Curry L.

AU - Langford, Carol A.

AU - McKinnon-Maksimowicz, Kathleen

AU - McAlear, Carol A.

AU - Monach, Paul A.

AU - Seo, Philip

AU - Warrington, Kenneth J

AU - Ytterberg, Steven R

AU - Merkel, Peter A.

AU - Matteson, Eric Lawrence

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Objective. To evaluate the performance of the Birmingham Vasculitis Activity Score (BVAS) in the assessment of disease activity in giant cell arteritis (GCA). Methods. Patients with GCA enrolled in a prospective, multicenter, longitudinal study with symptoms of active vasculitis during any visit were included. Spearman's rank correlation was used to explore the association of the BVAS with other measures of disease activity. Results. During a mean (SD) followup of 2.3 (1.6) years, symptoms of active GCA were present in 236 visits in 136 subjects (100 female, 74%). Median (range) BVAS1 (new/worse symptoms) was 1 (0-10) and median (range) BVAS2 (persistent symptoms) was 0 (0-5). Median (range) physician's global assessment (PGA) was 4 (0-9) for disease activity in the past 28 days and 2 (0-9) for activity on the day of the visit. Important ischemic manifestations of active vasculitis not recorded by the BVAS included tongue/jaw claudication (27%), upper extremity claudication (15%), lower extremity claudication (5%), carotidynia (7%), and ischemic retinopathy (5%). During 25 visits (11%) with active disease, all symptoms of active vasculitis were placed in the "Other" category yet still resulted in a BVAS1 and BVAS2 of 0. BVAS1 moderately correlated with PGA for the past 28 days (Spearman's correlation 0.50) and physician-rated disease activity for the past 28 days (Spearman's correlation 0.46). Conclusion. The BVAS has limited utility in GCA. Patients with active GCA can have a BVAS of 0. Many important ischemic symptoms attributable to active vasculitis are not included in the composite score.

AB - Objective. To evaluate the performance of the Birmingham Vasculitis Activity Score (BVAS) in the assessment of disease activity in giant cell arteritis (GCA). Methods. Patients with GCA enrolled in a prospective, multicenter, longitudinal study with symptoms of active vasculitis during any visit were included. Spearman's rank correlation was used to explore the association of the BVAS with other measures of disease activity. Results. During a mean (SD) followup of 2.3 (1.6) years, symptoms of active GCA were present in 236 visits in 136 subjects (100 female, 74%). Median (range) BVAS1 (new/worse symptoms) was 1 (0-10) and median (range) BVAS2 (persistent symptoms) was 0 (0-5). Median (range) physician's global assessment (PGA) was 4 (0-9) for disease activity in the past 28 days and 2 (0-9) for activity on the day of the visit. Important ischemic manifestations of active vasculitis not recorded by the BVAS included tongue/jaw claudication (27%), upper extremity claudication (15%), lower extremity claudication (5%), carotidynia (7%), and ischemic retinopathy (5%). During 25 visits (11%) with active disease, all symptoms of active vasculitis were placed in the "Other" category yet still resulted in a BVAS1 and BVAS2 of 0. BVAS1 moderately correlated with PGA for the past 28 days (Spearman's correlation 0.50) and physician-rated disease activity for the past 28 days (Spearman's correlation 0.46). Conclusion. The BVAS has limited utility in GCA. Patients with active GCA can have a BVAS of 0. Many important ischemic symptoms attributable to active vasculitis are not included in the composite score.

KW - Birmingham Vasculitis Activity Score

KW - Cohort Study

KW - Disease Activity

KW - Giant Cell Arteritis

UR - http://www.scopus.com/inward/record.url?scp=84973277735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973277735&partnerID=8YFLogxK

U2 - 10.3899/jrheum.151063

DO - 10.3899/jrheum.151063

M3 - Article

C2 - 27036388

AN - SCOPUS:84973277735

VL - 43

SP - 1078

EP - 1084

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 6

ER -